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ABSTRACT Mice with a targeted disruption in the f32-
microglobulin (f32m) gene, which lack major histocompatibility
complex class I molecules and consequently fail to develop
functional CD8 T cells, provided a useful model for assessing
the role ofclass I-restricted T cells in resistance to infection with
virulent Mycobacterium tuberculosis. OfmutantP2m-/- mice
infected with virulent 106 M. tuberculosis, 70% were dead or
moribund after 6 weeks, while all control mice expressing the
P2m gene remained alive for >20 weeks. Granuloma formation
occurred in mutant and control mice, but far greater numbers
of tubercle bacilli were present in the lungs ofmutant mice than
in controls, and caseating necrosis was seen only in P2m -/-
lungs. In contrast, no differences were seen in the course of
infection of mutant and control mice with an avirulent vaccine
strain, bacille Calmette-Guirin (BCG). Immunization with
BCG vaccine prolonged survival of I2m-/- mice after chal-
lenge with M. tuberculosis for 4 weeks but did not protect them
from death. These data indicate that functional CD8 T cells,
and possibly T cells bearing y6 antigen receptor, are a neces-
sary component of a protective immune response to M. tuber-
culosis in mice.
The reemergence of tuberculosis has added a new urgency to
understanding the protective immune responses to this disease
(1). Virtually all experimental data indicate that cell-mediated
rather than humoral immunity is the essential immune re-
sponse for resistance to Mycobacterium tuberculosis infection
(2, 3), and that CD4 T cells are necessary to that resistance
(4-6); it remains unclear whether they are sufficient. The roles
ofCD8 and y8T cells in the control oftuberculosis are less well
understood. Data on the question are conflicting, suggesting
that either CD4 (4, 6, 7) or CD8 (7, 8) T cells are sufficient for
protection, or that both subsets are necessary (5, 9).
The construction of a mouse which has a targeted disruption
of the gene for 02-microglobulin (%2m-/-) (10) has allowed the
development of a murine system in which to examine critically
the role of CD8 T cells in M. tuberculosis infection. This
deletion results in the failure to express functional class I major
histocompatibility complex (MHC) molecules and, conse-
quently, in a paucity ofCD8 cells due to the absence ofpositive
antigen selection. Because the 832m-/- mice are devoid of
MHC class I-restricted T cells, including cytotoxic T lympho-
cytes (CTLs), we thought that they might represent a useful in
vivo model in which to address the question of the role MHC
class I-restricted T cells in M. tuberculosis infection.
MATERIALS AND METHODS
Mice. Six- to eight-week-old C57BL/6 (National Cancer
Institute), 129 (The Jackson Laboratory), and 132m-/- mice
(bred as homozygotes) were used. All mice were maintained
in a specific-pathogen-free environment and were found to be
free of all 12 mouse pathogens tested.
Bacterial Strains and Mouse Infections. Bacille Calmette-
Guerin (BCG, Pasteur strain) and virulent M. tuberculosis
(Erdman strain) were obtained from the Trudeau Institute
(Lake Saranac, NY) and stored at -70'C until use. BCG and
M. tuberculosis cells in phosphate-buffered saline (PBS)
containing 0.05% Tween 80 were briefly sonicated before
injection into mice (106 bacteria per mouse, i.v.).
Organ Harvesting. Lungs, spleens, and livers were har-
vested from mice, homogenized in PBS/0.05% Tween 80
with a Stomacher homogenizer (Tekmar, Cincinnati), and
plated on supplemented 7H10 medium (Difco). For frozen
sections, tissues were embedded in OCT (Miles), flash frozen
in liquid nitrogen, and stored at -70'C.
Histology. Sections (5 Atm) from paraffin blocks containing
lung, liver, and spleen were cut and stained with hematoxylin
and eosin or by the Ziehl-Neelsen method for acid-fast bacilli
(AFB). The mean number ofAFB was evaluated by counting
the organisms within granulomas in 20 random x400 fields for
each section. Liver and spleen sections were evaluated for
granulomas per 10 random x 100 fields. Ten random granu-
lomas were examined for mean number of AFB.
Immunohistochemistry. Frozen 5-pum sections of lung were
mounted on poly(L-lysine)-coated slides and fixed in cold
acetone. Sections were blocked with rabbit serum and incu-
bated at 40C with rat anti-mouse CD4 or CD8 monoclonal
antibodies (10 Ag/ml). The secondary antibody was biotiny-
lated rabbit anti-rat IgG, and the staining was by the avidin-
biotin-peroxidase complex method with diaminobenzidine as
substrate.
Cytokine Assays. Spleen cells from mice 2-3 weeks post-
infection were stimulated with either Con A (5 Ag/ml),
tuberculin purified protein derivative (PPD, 10 ,ug/ml), or M.
tuberculosis sonicate (10 ,ug/ml). Culture supernatants har-
vested at 48 hr and sera (from five mice) were filtered through
0.45-/Lm filters, and interferon y (IFN-y) and tumor necrosis
factor a (TNF-a) production determined by ELISA (Gen-
zyme).
RESULTS
M. tuberculosis Infection in 132m-/- and Control Mice.
Mice with a disruption in both copies of the f32m gene (10)
were backcrossed to the C57BL/6 background. f32m-/-
mice and C57BL/6 control mice were infected with 106 M.
Abbreviations: AFB, acid-fast bacilli; CTL, cytotoxic T lymphocyte;
BCG, bacille Calmette-Gudrin;,82m, ,82-microglobulin; MHC, major
histocompatibility complex; cfu, colony-forming units; PPD, tuber-
culin purified protein derivative; IFN, interferon; TNF, tumor ne-
crosis factor.
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tuberculosis bacteria i.v. By 6 weeks, 70% of the P2m-/-
mice were dead or moribund (Fig. 1). In contrast, all
C57BL/6 mice survived >20 weeks. In histological sections,
the number of AFB per field was consistently 10-1000 times
higher in p2m-/- mice than in C57BL/6 mice. Colony
counts from spleen, liver, and lungs of the mice did not
consistently reflect the number of AFB seen in histological
sections, although at later time points a 10-fold difference in
colony-forming units (cfu) was seen between P2m-/- and
C57BL/6 mice (Fig. 2a). We attribute this inconsistency to
technical difficulties in disrupting infected cells in organs
without creating an aerosol.
Histological sections oflung tissue from both 132m-/- and
control mice had well-demarcated granulomas composed of
clusters of epitheloid macrophages with intervening collec-
tions of lymphocytes at 3 weeks postinfection. The morphol-
ogy of the granulomas in the control and 82m-/- mice was
very similar, but lung sections from P2m-/- mice showed
significantly more AFB inside the granulomas than those
from C57BL/6 mice (Fig. 3). Macrophages were frequently
completely full of AFB in the P2m-/- lung sections,
whereas the C57BL/6 macrophages generally contained 1-5
AFB per infected macrophage. By 6 weeks postinfection 70%o
of the lung volume was taken up by merging granulomas in
the sections from (32m-/- mice, compared with -30%o in the
control mouse sections. f32m-/- sections contained CD4-
positive cells within the granulomas and alveolar spaces, but
CD8-staining cells were absent. Granulomas from the control
mice stained positively for both CD4 and CD8 cells (Fig. 3).
Histological examination of the liver and spleen from
P2m-/- and control mice showed well-formed granulomas,
with a central core of epitheloid macrophages rimmed by
lymphocytes. P2m-/- liver and spleen sections showed an
-10-fold increase in AFB compared with the control.
When (2m-/- mice judged to be within 4-5 days of death
were sacrificed for histology, the lung sections revealed large
confluent necrotizing granulomas occupying 60-80%o of the
lung volume. Necrosis and extracellular AFB were promi-
nent within the center of the granulomas, whereas the pe-
ripheral zone consisted of apparently viable macrophages
containing numerous intracellular AFB, lymphocytes, and
neutrophils. Most strikingly, necrosis was not seen in control
mice.
Although the f32m-/- mice had been backcrossed to a
C57BL/6 background, the progeny still contained some
genes of the 129 parental strain. C57BL/6 mice, the back-
cross background strain, were routinely used as control










genes present in the .82m-/- mice might affect the outcome
of a M. tuberculosis infection, we compared infection ofboth
parental strains, C57BL/6 and 129, with infection of the
P32m-/- mice. Strain 129 mice were similar to C57BL/6 mice
with respect to cfu and mortality following infection (data not
shown). Thus, it appeared that the uncontrolled M. tubercu-
losis growth and mortality seen in the infected 2m-/- mice
was primarily the result of the defect in class I expression,
and not of the 129 background.
BCG Infection in 12n-/- and Control Mice. BCG, the
avirulent Mycobacterium bovis vaccine strain, is frequently
used as an experimental model for M. tuberculosis infection.
Following infection of ,B2m-/- and C57BL/6 mice with
BCG, no mortality or differences in cfu from the spleen, liver,
or lungs among the strains of mice were observed up to 28
weeks postinfection (Fig. 2c). In lung sections taken from
P2m-/- and C57BL/6 mice immunized with BCG for 8
weeks, well-formed granulomas and very few AFB were
seen. In contrast to infection with virulent M. tuberculosis,
the course of BCG infection was not altered perceptibly by
the absence of CD8 T cells.
M. tuberculosis Infection Following BCG Inuization in
im-/- Mice. We explored whether immunization with
BCG could engender protection in p2m-/- mice. Both
,82m-/- and C57BL/6 mice were immunized with BCG
vaccine 8 weeks prior to challenge with M. tuberculosis. By
9 weeks after the M. tuberculosis challenge, 70%6 of the
Pm-/- mice had died (Fig. 1). In contrast, all of the
C57BL/6 mice survived >20 weeks. At 10 weeks postinfec-
tion, (2m-/- lungs showed a 10-fold increase in M. tuber-
culosis cfu relative to C57BL/6 lungs (Fig. 2b). Granuloas
from both 2m-/- and C57BL/6 mice appeared morpho-
logically similar, and AFB from lung sections showed a
100-fold increase in bacterial load in the 2m-/- mice
compared with control mice. Thus, immunization with BCG
increased survival time forM. tuberculosis-infected 32nm-/-
mice by 3-5 weeks but did not protect the mice from death.
Cytkine Production in 132M-/- Mice Infected with M.
tuberculosis. Both IFN-y and TNF-a are required for activa-
tion of macrophages to produce reactive nitrogen intermedi-
ates and to kill ingested M. tuberculosis (11-13). Since CD8
T cells are known to make IFN-y, the production of those
cytokines was examined in 82m-/- and control mice in-
fected with M. tuberculosis. IFN-y and TNF-a production
did not differ significantly between spleen cells from
P2m-/- and C57BL/6 mice stimulated in vitro with Con A
or M. tuberculosis sonicate, although stimulation with PPD
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FIG. 1. Survival curves of 2m-/- (i) and C57BL/6 (e) mice infected with M. tuberculosis (24 mice per group) (a) or immunized with BCG
and challenged with M. tuberculosis i.v. (12 mice per group) (b). Number of moribund or dead mice is indicated in parentheses beside each point.
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FIG. 2. Bacterial load (cfu) per organ [spleen (Top), liver (Middle), and lungs (Bottom)] in fi2m-/- (m) and C57BL/6 (o) mice after M.
tuberculosis challenge (a), immunization with BCG and challenge with M. tuberculosis (b), or infection with BCG (c). Four mice per time point
were sacrificed. Experiments were repeated at least twice.
production in cells from C57BL/6 mice relative to 82m-/-
cells (Table 1). Neither cytokine was produced in unstimu-
lated spleen cells, nor did cells from uninfected mice respond
to PPD or M. tuberculosis sonicate. Although not all infected
mice had detectable cytokines in their sera, average IFN-y
levels in sera from 132m-/- were slightly lower than in sera
from C57BL/6 mice, while serum levels of TNF-a did not
differ between the two mouse strains. Thus the qualitative
differences in the course of infection in 12m-/- and control
mice cannot be explained by different levels of production of
these two important cytokines.
DISCUSSION
Defining the immune responses necessary and sufficient for
protection against M. tuberculosis infection is an urgent
scientific problem. All studies suggest that CD4 T cells play
a vital role in the response to this pathogen (4-6). Cytokines,
such as TNF-a and IFN-y, are also important in the control
and pathology ofM. tuberculosis infection (13, 14). However,
the importance ofCD8 T cells in protection and pathogenesis
in tuberculosis has been problematic. Adoptive transfer and
in vivo T-cell subset depletion studies have suggested that
CD8 T cells (8), CD4 T cells (5, 6, 15), or both (7, 9, 16) are
involved in controlling M. tuberculosis infection. In vitro
studies indicate that murine CD8 T-cell lines from mice
infected with mycobacteria are cytolytic for macrophages
infected with live or dead mycobacteria (17, 18), yet their
ability to provide protection in vivo against M. tuberculosis
challenge has not been established. We chose a genetic model
in which mice fail to express MHC class I molecules on their
cell surface, and therefore lack CD8 T cells, to assess the
importance of MHC class I-restricted T cells to protection
from experimental M. tuberculosis infection.
In this study, we observed a profound difference in the
course of infection with M. tuberculosis between the
f32m-/- mice and control mice. The control mice survived
the M. tuberculosis challenge for >20 weeks, while the
majority of 82mm-/- mice did not survive beyond 6 weeks.
BCG immunization provided some initial protection against
a virulent M. tuberculosis challenge in P2m-/- mice, as
reflected in an increased survival time of 3-4 weeks. There
was a reduction in bacterial load in control and 12m-/- mice
immunized with BCG, but this was not sufficient to prevent
death in p2m-/- mice. Thus, a major difference in the
response of P2m-/- mice to a tuberculosis infection, com-
pared with either parent (C57BL/6 or 129) strain, was seen,
indicating that the 32m-/- defect is responsible for the
decreased survival and increased pathology in M. tubercu-
losis-infected mutant mice.
Although the P2m- mutation caused a significant reduc-
tion in the ability ofthe mice to control a virulent tuberculosis
infection, the lack of class I MHC expression did not com-
promise the ability to control BCG infection. This points to
an important difference between BCG and virulent M. tu-
berculosis strains in terms of their interaction with the host.
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FIG. 3. Histology and immunohistochemistry of lung sections from C57BL/6 (a, c, and e) and 2m-/- (b, d, f, g, and h) mice. (a and b)
Ziehl-Neelsen staining for AFB in granuloma; arrows indicate AFB. (x250.) (c and d) Immunohistochemistry with rat anti-mouse CD4. (x250.)
(e andf) Immunohistochemistry with rat anti-mouse CD8. (x250.) (g) Ziehl-Neelsen staining of necrotizing granuloma in 2m-/- lung section.
(x63.) (h) Ziehl-Neelsen staining of P2m-/- lung section showing tuberculous bronchopneumonia. (x250.)
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Table 1. Cytokine production in spleen cells from C57BL/6 and P2m-/- mice
IFN-y, Ag/ml TNF-a, pg/ml
Mice Con A PPD Sonicate Con A PPD Sonicate
C57BL/6 31.7 + 10.2* 15.7 ± 4.7** 16.1 ± 5.2* 235.0 + 48.0* 201.7 + 25.9* 476.7 ± 50.9*
P82m-/- 13.7 ± 5.6 004.5 ± 0.9 8.2 ± 2.4 191.7 ± 46.4 86.7 + 13.3 600 ± 47.3
Spleen cells were stimulated with Con A, PPD, or M. tuberculosis sonicate. *, P-. 0.05; **, P = 0.02.
Histopathological examination of 32m-/- lungs showed that
comparable granuloma formation occurred following either
BCG immunization or tuberculosis infection. Most AFB
were contained inside granulomas, but the replication of M.
tuberculosis in the P2m-/- granulomas was uncontrolled.
Most strikingly, only 832m- mice had extensive caseating
necrosis of the lung tissue, characterized by numerous ne-
crotizing granulomas and large numbers of AFB, many of
which appeared to be extracellular amidst necrotic cell
debris. Necrosis was not seen in control (C57BL/6 or 129)
mice. The presence of necrosis appeared to correlate in-
versely with survival of the mouse.
An intrinsic limitation of the P2m-/- mouse model is that
it is not possible to reconstitute the defect by adding back
CD8 T cells to the mice; the lack of functional class I MHC
molecules precludes presentation by potential targets, even
to presensitized CD8 T cells, and thus prevents the expansion
or functioning of repopulating cells. While CD8 CTLs have
not been found in the P2m-/- mice (19, 20), it is not possible
in the present model to establish formally that the lack of
class I-restricted CD8 CTLs is responsible for the increase in
mortality in a M. tuberculosis infection in these mice. Since
there is no known defect in MHC class II-restricted CTLs
(19, 20) or lymphokine production (21) in 2m-/- mice, our
results indicate that CD4 T cells are not sufficient to control
M. tuberculosis infection in mice. Natural killer cells are also
present in 82m-/- mice (20, 22) and have been found to
increase markedly in 2m-/- mice infected with Toxo-
plasma gondii (F. Y. Denkers, R. T. Gazzinelli, and A. Sher,
personal communication). We challenged beige mice, defec-
tive in natural killer cell function, with M. tuberculosis and
observed no significant differences in survival between
C57BL/6 bg/bg and C57BL/6 control mice, up to 20 weeks
(J.L.F. and K.J.T., unpublished data).
The most obvious interpretation of the present results is
that CD8 T cells are functioning as MHC class I-restricted
CTLs in aM. tuberculosis infection, and the absence ofCTLs
results in an increase in bacterial load and pathology in the
mouse. As Kaufmann (18) has suggested from in vitro data,
CTLs may be functioning in bacterial infections in vivo to lyse
highly infected macrophages and disperse the bacteria to
macrophages that can be activated. Some y8 T cells have
been shown to recognize mycobacterial antigens (23), and
also MHC class Ia antigens, such as TL and Qal (24), which
may require (32m for expression, but their recognition of
antigen has not been reported to be MHC class I-restricted.
Nevertheless, the possibility that their activity is diminished
in P2m-/- mice cannot be excluded. Similarly, the existence
of a subset of CD8 T cells producing cytokines uniquely
necessary for the activation of macrophages cannot be ex-
cluded on the basis of present results. However, dramatic
differences in IFN-y and TNF-a levels between the 2m-/-
and control mice were not seen.
The present results establish that MHC class I-restricted T
cells are necessary for protection against a virulent M.
tuberculosis infection in mice. They raise more general
questions, including whether BCG is a useful challenge
model for M. tuberculosis vaccine studies and whether BCG
vaccines can effectively engender the functional CD8 or y8T
cells required for protection against M. tuberculosis. The
results also emphasize the need to define the antigen speci-
ficity of cytotoxic CD8 T cells in tuberculosis, and suggest
that new vaccines may be developed that are more effective
in generating the appropriate protective T-cell response.
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